<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0055">
 <label>55</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Baker</surname>
    <given-names>AF</given-names>
   </name>, 
   <name name-style="western">
    <surname>Adab</surname>
    <given-names>KN</given-names>
   </name>, 
   <name name-style="western">
    <surname>Raghunand</surname>
    <given-names>N</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers</article-title>. 
  <source>Invest New Drugs</source>
  <year>2013</year>;
  <volume>31</volume>:
  <fpage>631</fpage>–
  <lpage>41</lpage>.
  <pub-id pub-id-type="pmid">22711542</pub-id>
 </mixed-citation>
</ref>
